Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?

por Brabers, Anne EM, Moors, Ellen HM, van Weely, Sonja, de Vrueh, Remco LA
Publicado 2011

Predictors of orphan drug approval in the European Union

por Heemstra, Harald E., de Vrueh, Remco L., van Weely, Sonja, Büller, Hans A., Leufkens, Hubert G. M.
Publicado 2008

From rationing to rationality: an n-of-one trial service for off-label medicines for rare (neuromuscular) diseases

por Weinreich, Stephanie S, Vrinten, Charlotte, Verschuuren, Jan JGM, Uyl-de Groot, Carin A, Kuijpers, Marja R, Sterrenburg, Ellen, Scholten, Rob JPM, van Bezooijen, Cees FRM, Timmen, Marcel FTH, van Weely, Sonja, Cornel, Martina C
Publicado 2012